LENSAR, Inc. (LNSR): Price and Financial Metrics
GET POWR RATINGS... FREE!
LNSR Stock Summary
- With a market capitalization of $24,314,718, LENSAR INC has a greater market value than only 9.55% of US stocks.
- LNSR's went public 2.48 years ago, making it older than only 11.78% of listed US stocks we're tracking.
- The volatility of LENSAR INC's share price is greater than that of 87.87% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to LENSAR INC, a group of peers worth examining would be MXCT, CASI, VMEO, SMRT, and CDNA.
- To check out LENSAR INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001320350.
LNSR Valuation Summary
- In comparison to the median Healthcare stock, LNSR's price/earnings ratio is 105.17% lower, now standing at -1.2.
- Over the past 30 months, LNSR's price/earnings ratio has gone up 5.3.
Below are key valuation metrics over time for LNSR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LNSR | 2023-03-24 | 0.7 | 0.6 | -1.2 | -0.6 |
| LNSR | 2023-03-23 | 0.7 | 0.6 | -1.3 | -0.7 |
| LNSR | 2023-03-22 | 0.7 | 0.6 | -1.2 | -0.6 |
| LNSR | 2023-03-21 | 0.7 | 0.6 | -1.3 | -0.7 |
| LNSR | 2023-03-20 | 0.7 | 0.6 | -1.3 | -0.7 |
| LNSR | 2023-03-17 | 0.8 | 0.7 | -1.5 | -0.9 |
LNSR Price Target
For more insight on analysts targets of LNSR, see our LNSR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.00 | Average Broker Recommendation | 1 (Strong Buy) |
LNSR Stock Price Chart Interactive Chart >
LNSR Price/Volume Stats
| Current price | $2.41 | 52-week high | $8.55 |
| Prev. close | $2.22 | 52-week low | $1.90 |
| Day low | $2.20 | Volume | 14,512 |
| Day high | $2.56 | Avg. volume | 22,386 |
| 50-day MA | $2.90 | Dividend yield | N/A |
| 200-day MA | $4.53 | Market Cap | 26.76M |
LENSAR, Inc. (LNSR) Company Bio
LENSAR, Inc. develops laser technologies. The Company provides autoprecision laser and proprietary 3-D imaging, measurement, and guidance system for refractive cataract surgery. LENSAR serves the healthcare industries throughout the United States.
Latest LNSR News From Around the Web
Below are the latest news stories about LENSAR INC that investors may wish to consider to help them evaluate LNSR as an investment opportunity.
LENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call TranscriptLENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to turn the conference over […] |
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateORLANDO, Fla., March 16, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. |
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023ORLANDO, Fla., March 09, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, March 16, 2023 to discuss the financial results |
LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 ResultsORLANDO, Fla., February 14, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of its ALLY® Adaptive Cataract Treatment System. |
LENSAR to Present at Two Upcoming Investor ConferencesORLANDO, Fla., November 22, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences: |
LNSR Price Returns
| 1-mo | -19.93% |
| 3-mo | -12.36% |
| 6-mo | -56.81% |
| 1-year | -70.61% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -18.58% |
| 2022 | -50.58% |
| 2021 | -17.38% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...